Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sex hormone effects on marrow and visceral adiposity in transgender adults
NL-OMON55733Phase 4Active, not recruiting
- Sponsor
- Vrije University Medical Center
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of estradiol, testosterone and cyproterone in gender dysphoria (GD) (4 arms), sponsored by Vrije University Medical Center. Primary endpoint: Change in vertebral bone marrow fat fraction. Started May 2019; status: active, not recruiting.
02
Drugs
estradioltestosteronecyproterone
03
Conditions
gender dysphoria (GD)
Beyond the preview
Go deeper on NL-OMON55733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55733.